Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716285 | 1.00 | MEN1 (1.00) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL4760580 | 0.98 | MEN1 (0.97) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL4761472 | 0.95 | MEN1 (0.91) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL11167834 | 0.87 | MEN1 (0.76) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL11173490 | 0.87 | MEN1 (0.76) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL4716013 | 0.87 | MEN1 (0.76) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL15733981 | 0.86 | MEN1 (0.76) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL11183258 | 0.85 | MEN1 (0.74) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL4714278 | 0.85 | KMT2A (0.74) | MEN1KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL19683494 | 0.85 | KMT2A (0.74) | MEN1KMT2ALMNAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| CN-113444063-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113321632-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-2890375-B1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-28 | — | — | EP | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-28 | — | — | US | disclosed |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-08-13 | — | — | US | disclosed |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-06-09 | — | — | US | disclosed |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-10 | — | — | US | disclosed |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| WO-2014033170-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033176-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
| US-4377521-A | ANTILIPEMIC | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4138399-A | Sulfamylbenzoic acid | PFIZER INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4124590-A | CARDIOVASCULAR DISORDERS, ANTILIPEMIC AGENTS | PFIZER INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-3992441-A | ANTILIPEMIC | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | MEN1 4633/4885KMT2A 3726/4885LMNA 4722/4885 |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | MEN1 3634/4885KMT2A 543/4885LMNA 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.